WHO ICTRP trial
Clinical and metabolic effects of rosiglitazone and metformin in non-obese women…
ChiCTR-TRC-13003529 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR-TRC-13003529 |
|---|---|
| Public title | Clinical and metabolic effects of rosiglitazone and metformin in non-obese women with polycystic ovary syndrome and metabolic disorders: a randomized controlled trial |
| Scientific title | Clinical and metabolic effects of rosiglitazone and metformin in non-obese women with polycystic ovary syndrome and metabolic disorders: a randomized controlled trial |
| Primary sponsor | West China Second University Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | Post-market |
| Countries | China |
| Conditions | polycystic ovary syndrome |
| Interventions | A:metformin (500mg, tid, 6months);B:rosiglitazone 4mg, qd, 6months |
| Registration date | Aug 17, 2013 |
| Target size | A:100;B:100 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: